Terms and Agreement
Please agree to the terms to continue using the chat feature.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Our lead development programs include two Phase 2 clinical programs and multiple upcoming Phase 1 clinical trials anticipated for 2023. We have also established a wholly-owned subsidiary, Starlight Therapeutics Inc., to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates are estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.
Lantern Pharma is revolutionizing the fields of oncology drug discovery and development through its proprietary AI and machine learning platform, RADR®. Utilizing an extensive dataset of over 25 billion oncology-centric data points and a library of more than 200 advanced machine learning algorithms, the company addresses multi-billion-dollar challenges in the oncology drug development landscape. With guidance from an elite team of scientific advisors and collaborators, Lantern Pharma has expedited its growing portfolio of treatments. This includes eleven distinct cancer indications as well as an antibody-drug conjugate program. Remarkably, new drug programs propelled by Lantern Pharma's technology advance from initial AI-derived insights to first-in-human clinical trials within a 2-3 year time frame and at a cost of approximately $1.0-2.0 million per program. The company's AI-empowered pipeline has an estimated combined annual market potential exceeding $15 billion USD and holds the promise of delivering transformative therapies to hundreds of thousands of cancer patients.
Red Chat is here to summarize the SEC filing data on LTRN
Please agree to the terms to continue using the chat feature.